CDK4 and breast cancer: Strikingly, CDK4, the primary target of CDK4/6 inhibitors that showed a major clinical impact in ER-positive breast cancers, was classified as “strongly selective” in both CRISPR and RNAi panels, with the selectivity primarily associated with ER-positive cell lines, Ewing sarcoma and breast cancer (not shown).